These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 8722345

  • 21. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
    Kaijser GP, Keizer HJ, Beijnen JH, Bult A, Underberg WJ.
    Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
    [Abstract] [Full Text] [Related]

  • 22. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME, Huitema AD, Tukker AC, van Dam SM, Rodenhuis S, Beijnen JH.
    Clin Cancer Res; 2005 Jan 01; 11(1):273-83. PubMed ID: 15671556
    [Abstract] [Full Text] [Related]

  • 23. Protective effect of aminoguanidine against oxidative stress and bladder injury in cyclophosphamide-induced hemorrhagic cystitis in rat.
    Abraham P, Rabi S, Selvakumar D.
    Cell Biochem Funct; 2009 Jan 01; 27(1):56-62. PubMed ID: 19107871
    [Abstract] [Full Text] [Related]

  • 24. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
    Olver I, Keefe D, Myers M, Caruso D.
    Chemotherapy; 2005 May 01; 51(2-3):142-6. PubMed ID: 15886474
    [Abstract] [Full Text] [Related]

  • 25. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M.
    Clin Cancer Res; 2000 Jan 01; 6(1):57-63. PubMed ID: 10656432
    [Abstract] [Full Text] [Related]

  • 26. Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support.
    Meisenberg B, Lassiter M, Hussein A, Ross M, Vredenburgh JJ, Peters WP.
    Bone Marrow Transplant; 1994 Aug 01; 14(2):287-91. PubMed ID: 7994244
    [Abstract] [Full Text] [Related]

  • 27. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 28. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
    Otero JC, Solidoro A, Casanova L, Vallejos C, Rodriguez W.
    J Exp Ther Oncol; 1996 Mar 01; 1(2):84-7. PubMed ID: 9414391
    [Abstract] [Full Text] [Related]

  • 29. Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: A cohort study and comprehensive literature review.
    Almalag HM, Alasmari SS, Alrayes MH, Binhameed MA, Alsudairi RA, Alosaimi MM, Alnasser GA, Abuzaid RA, Khalil N, Abouzaid HH, Alarfaj AS.
    J Oncol Pharm Pract; 2021 Mar 01; 27(2):340-349. PubMed ID: 32356687
    [Abstract] [Full Text] [Related]

  • 30. Mesna excretion and ifosfamide nephrotoxicity in children.
    Goren MP, Pratt CB, Meyer WH, Wright RK, Dodge RK, Viar MJ.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7153-7. PubMed ID: 2510931
    [Abstract] [Full Text] [Related]

  • 31. N-acetylcysteine and sodium 2-mercaptoethane sulfonate as sources of urinary thiol groups in the rat.
    Ormstad K, Ohno Y.
    Cancer Res; 1984 Sep 15; 44(9):3797-800. PubMed ID: 6430554
    [Abstract] [Full Text] [Related]

  • 32. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
    Tiersten A, Wo J, Jacobson C, Weitzman A, Horwich T, Hesdorffer C, Savage D, Troxel A.
    Breast; 2004 Aug 15; 13(4):341-6. PubMed ID: 15325671
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics of continuous-infusion high-dose thiotepa.
    Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K.
    Cancer Treat Rep; 1987 Nov 15; 71(11):1043-7. PubMed ID: 3119200
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
    Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J, Hausheer FH, van der Vijgh WJ.
    Clin Pharmacol Ther; 2003 Aug 15; 74(2):157-69. PubMed ID: 12891226
    [Abstract] [Full Text] [Related]

  • 35. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J.
    Clin Cancer Res; 1996 Mar 15; 2(3):493-9. PubMed ID: 9816195
    [Abstract] [Full Text] [Related]

  • 36. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
    Kushner BH, Cheung IY, Kramer K, Modak S, Cheung NK.
    Pediatr Blood Cancer; 2007 Apr 15; 48(4):430-4. PubMed ID: 16421906
    [Abstract] [Full Text] [Related]

  • 37. Bioavailability of orally administered mesna.
    Burkert H, Lücker PW, Wetzelsberger N, Breuel HP.
    Arzneimittelforschung; 1984 Apr 15; 34(11):1597-600. PubMed ID: 6441581
    [Abstract] [Full Text] [Related]

  • 38. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.
    Fleming GF, Waggoner SE, Rotmensch J, Skoog LA, Langhauser C.
    Gynecol Oncol; 1997 Apr 15; 65(1):42-5. PubMed ID: 9103389
    [Abstract] [Full Text] [Related]

  • 39. Hemorrhagic cystitis after conditioning for bone marrow transplantation and its prophylaxis.
    Moriyama Y, Koike T, Shibata A.
    Jpn J Clin Oncol; 1984 Dec 15; 14 Suppl 1():531-6. PubMed ID: 6441037
    [Abstract] [Full Text] [Related]

  • 40. Cyclophosphamide-induced hemorrhagic cystitis in young patients with solid tumors: A single institution study.
    Saito Y, Kumamoto T, Shiraiwa M, Sonoda T, Arakawa A, Hashimoto H, Tamai I, Ogawa C, Terakado H.
    Asia Pac J Clin Oncol; 2018 Oct 15; 14(5):e460-e464. PubMed ID: 29989294
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.